Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

ELOX

Eloxx Pharmaceuticals Inc

18.49

Aug 04 • 11:35 AM ET +0.04 (0.22%)

Healthcare Biotechnology USA Nano NASD

Held by: VTI VXF

Scroll to Statements

Index	-
Market Cap	0.77M
Enterprise Value	-5.60M
Income	-
Sales	-
Book/sh	-16.44
Cash/sh	152.63
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	10
IPO	Dec 11, 1998

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	0.12
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	0.48
Current Ratio	0.48
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	75.85% 61.60%
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	97.33%
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	40.89% -

Insider Own	46.25%
Insider Trans	0.00%
Inst Own	-
Inst Trans	20.81%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	42.19%
SMA50	67.41%
SMA200	510.22%
Trades

Shs Outstand	0.46M
Shs Float	-
Short Float	-
Short Ratio	0.24
Short Interest	0.01M
52W High	19.36 -4.48%
52W Low	- -
Volatility	19.76% 16.47%
ATR (14)	2.16
RSI (14)	74.94
Beta	-146581.00
Rel Volume	1.41
Avg Volume	46.30K
Volume	23,279

Perf Week	44.34%
Perf Month	59.95%
Perf Quarter	834.36%
Perf Half Y	1680808.98%
Perf YTD	1680809.08%
Perf Year	1680808.98%
Perf 3Y	-75.21%
Perf 5Y	-96.77%
Perf 10Y	-98.74%
Recom	1.00
Target Price	41.50
Prev Close	18.45
Price	18.49
Change	0.22%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-20-26	Initiated	Guggenheim	Buy	$43

Eloxx Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of novel ribonucleic acid-modulating drug candidates. It focuses on the formulation of medicines to treat rare and ultra-rare premature stop codon diseases. The company was founded by Silvia Noiman on December 19, 2017 and is headquartered in Arlington, MA.

PresidentMr. Sumit Aggarwal M.B.A.

Interim Chief Financial OfficerMr. Daniel E. Geffken M.B.A.

VP & Head of Corporate DevelopmentMr. John Woolford

Chief Medical OfficerDr. Ali Hariri M.D.

VP & Head of Discovery SciencesDr. Roger Clark

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ELOX

Eloxx Pharmaceuticals Inc

Upgrade your Finviz experience